ENDRA Life Sciences Inc. (NDRA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$5.37

From 52W high−31.28%

Volume16235.00

Market cap$8.37M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$5.37

From 52W high

−31.28%

Volume

16235.00

Market cap

$8.37M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

48.9

MomentumView details →

1D Return

+2.98%

YTD Return

+15.89%

SummaryUpdated Jun 1, 2026

ENDRA Life Sciences Inc. (NASDAQ:NDRA) is a medical technology company founded in 2007 and based in Ann Arbor, Michigan. The company went public in June 2017 and focuses on developing advanced ultrasound imaging technology for medical diagnostics. ENDRA specializes in thermo-acoustic enhanced ultrasound (TAEUS) technology, which represents a novel approach to medical imaging that combines traditional ultrasound with photoacoustic principles to provide enhanced diagnostic capabilities for physicians.

Ask drillr about ENDRA Life Sciences Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−93.77%

ROA (TTM)

−74.50%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+52.76%

FCF YoY

−40.10%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+12.88%

EBITDA YoY

+3.98%

MomentumView details →

1D Return

+2.98%

YTD Return

+15.89%

1Y Return

+9.60%

RSI (14)

48.9

vs 50D SMA

+3.98%

vs 200D SMA

+10.68%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

7.10x

Quick Ratio

7.10x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.63

EPS Surprise

25.00%

Beats (12Q)

7/12

Next Q EPS Est

−$0.84

Avg Surprise (4Q)

−29.60%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−5.92M

Op. CF (TTM)

−4.82M

Next earningsNov 13, 2026 →

Latest newsMore news →

ENDRA Life Sciences Inc. reported its financial results for the second quarter ended June 30, 2026.34d ago

ENDRA Life Sciences Inc. completed a private placement raising gross proceeds of $50 million, with net proceeds of $3.8 million.35d ago

Similar companies

Advanced Biomed Inc. Common StockADVB Intelligent Bio Solutions Inc.INBS Mainz Biomed B.V.MYNZ Trinity Biotech plcTRIB bioAffinity Technologies, Inc.BIAF BioNexus Gene Lab Corp.BGLC Find similar companies →

Latest newsMore news →

ENDRA Life Sciences Inc. reported its financial results for the second quarter ended June 30, 2026.34d ago ENDRA Life Sciences Inc. completed a private placement raising gross proceeds of $50 million, with net proceeds of $3.8 million.35d ago ASP Isotopes proposed a merger with ENDRA Life Sciences.61d ago